Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7817MR)

This product GTTS-WQ7817MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7817MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5288MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD124
GTTS-WQ4971MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ7901MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK-249320
GTTS-WQ1434MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ5295MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ13663MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ13441MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ5157MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CAN34D3-65
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW